Roivant Sciences ROIV Cash Flow Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | -$955.47M-1,336% | -$523.69M-111% | -$637.58M-113% | -$318.93M-107% | ||
| $3.35M-76.2% | $4.14M-76.9% | $6.37M-68.7% | $10.29M-51.2% | $14.07M-36.1% | ||
| $346.17M+19.8% | $352.48M+39.7% | $331.17M+48.6% | $321.02M+60.1% | $289.03M+44.8% | ||
| $3.42M— | -$12.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $7.42M-15.3% | $7.75M+217% | $8.09M+309% | $8.42M+183% | $8.76M+153% | ||
| -$1.01M-230% | -$562.75K-3,210% | -$117.5K+85.4% | $327.75K+121% | $773K+132% | ||
| —— | -$23.42M— | -$8.73M— | $8.58M— | -$3.76M— | ||
| $85.05M+946% | $61.27M+1,311% | $37.5M+59,617% | $13.72M+178% | -$10.05M-201% | ||
| —— | $143.87M— | $100.96M— | $20.84M— | $55.19M— | ||
| $8.28M+20.9% | $8.38M+25.7% | $7.57M+13.1% | $7.21M+5.9% | $6.84M0.0% | ||
| —— | —— | —— | —— | -$8.85M— | ||
| -$2.39M+58.2% | -$2.35M+69.2% | -$3.58M+53.0% | -$4.36M+46.4% | -$5.7M+31.5% | ||
| -$11.46M— | —— | —— | —— | —— | ||
| -$750.35M+10.6% | -$759.1M+2.1% | -$769.86M+1.1% | -$851.01M-20.2% | -$839.45M-9.7% | ||
| —— | —— | $14.52M+445% | $7.67M+294% | $4.6M+233% | ||
| —— | —— | —— | —— | —— | ||
| $2.52M+3,287% | $1.81M+122% | $1.18M+115% | $550.5K+107% | -$79K+99.1% | ||
| $0-100% | $1.02B-66.7% | $2.03B0.0% | $3.05B+200% | $4.06B— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $853.14M+31.6% | $1.29B— | ||
| $0— | $217.17M— | $98.35M— | $27.79M— | $0— | ||
| $0-100% | $0-100% | $112K-91.4% | $445K-68.5% | $774K-50.0% | ||
| —— | —— | —— | -$746.95M-246% | -$1.22B-370% | ||
| $3.77M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $1.49M-78.8% | $2.98M-63.3% | $4.47M-51.3% | $5.96M-41.9% | ||
| —— | $45.26M-16.7% | $65.81M+163% | $81.02M— | $69.96M— | ||
| -$47.7M— | -$33.58M— | —— | —— | —— | ||
| —— | $143.87M— | $100.96M— | $20.84M— | $55.19M— | ||
| $0-100% | $0— | $0— | $0— | $110.39M— | ||
| —— | —— | —— | —— | $376.51M— | ||
| $3.42M— | -$12.9M— | —— | —— | —— | ||
| $0— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $770.24M— | $577.68M— | $385.12M— | $192.56M— | $0— | ||
| -$2.39M+58.2% | -$2.35M+69.2% | -$3.58M+53.0% | -$4.36M+46.4% | -$5.7M+31.5% | ||
| -$11.46M— | —— | —— | —— | —— | ||
| $15.59M— | $11.7M— | —— | —— | —— | ||
| $8.28M+20.9% | $8.38M+25.7% | $7.57M+13.1% | $7.21M+5.9% | $6.84M0.0% | ||
| —— | —— | -$33.18M-548% | -$9.27M+56.8% | -$3.76M+63.3% | ||
| —— | —— | —— | —— | —— | ||
| $2.52M+3,287% | $1.81M+122% | $1.18M+115% | $550.5K+107% | -$79K+99.1% | ||
| $0-100% | $1.02B-66.7% | $2.03B0.0% | $3.05B+200% | $4.06B— | ||
| $1.12B— | $841.73M— | $561.15M— | $280.58M— | $0— | ||
| —— | —— | —— | —— | $110.39M-97.9% | ||
| $0-100% | $0-100% | $112K-91.4% | $445K-68.5% | $774K-50.0% | ||
| $48.62M+30.6% | $47.33M-18.9% | $32.1M-39.5% | $34.08M-23.7% | $37.22M-1.3% | ||
| $193.61M— | $257.99M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $0-100% | $48.98M+177% | $50.48M+117% | $51.98M+78.3% | ||
| $0-100% | $23.29M+300% | $23.29M+300% | $0-100% | $11.65M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $57.69M— | $43.26M— | —— | —— | —— | ||
| $31.11M— | $23.34M— | $15.56M— | $7.78M— | $0— | ||
| -$758.56M+10.1% | -$766.86M+1.6% | -$784.38M-0.4% | -$858.67M-20.9% | -$844.05M-10.1% | ||
| -$758.56M+10.1% | -$766.86M+1.6% | -$784.38M-0.4% | -$858.67M-20.9% | -$844.05M-10.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Roivant Sciences generate?
- Roivant Sciences (ROIV) generated -$750.3M in operating cash flow over the trailing twelve months.
- What is Roivant Sciences's free cash flow?
- After $14.0M of capital expenditures, Roivant Sciences's free cash flow was -$758.6M over the trailing twelve months, up 10.1% year over year.
- Where does Roivant Sciences's cash flow data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
